Journal: Theranostics

Article Title: Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis

doi: 10.7150/thno.48080

Figure Lengend Snippet: hUC-MSCs treatment normalizes markers of senescence in MRL/ lpr mice splenic CD4+ T cells in vivo. (A, B) qPCR analysis showing the expression levels of p21, p16 in WT mice, PBS-treated MRL/ lpr mice and hUC-MSCs-treated MRL/ lpr mice. (C) Representative western blot showing the expression levels of p21, p16, p53 and acetylation of p53 in WT mice, PBS-treated MRL/ lpr mice and hUC-MSCs-treated MRL/ lpr mice. (D, E) Capillary WES and qPCR analysis showing the expression of Sirt1 in WT mice, PBS-treated MRL/ lpr mice and hUC-MSCs-treated MRL/ lpr mice. GAPDH was used as a protein loading control. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: The splenic CD4+ T cells were purified using immunomagnetic positive selection (EasySepTM mouse CD4+ positive selection Kit, 18952, Stemcell technologies, Canada).

Techniques: In Vivo, Expressing, Western Blot, Control

Journal: Theranostics

Article Title: Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis

doi: 10.7150/thno.48080

Figure Lengend Snippet: hUC-MSCs increase markers of senescence in splenic CD4+ T cells in vitro . (A-C) Splenic CD4+ T cells from MRL /lpr mice were cultured alone or with hUC-MSCs at ratios of 1:1, 10:1, or 50:1 for 48 h. (D-F) In further experiments, MRL/ lpr splenic CD4+ T cells and hUC-MSCs (10:1) were cultured separated by transwells. Sirt1 (A, D), p21 (B, E) and p16 (C, F) RNA levels of CD4+ T cells were quantitated by qPCR. All experimental data were verified in at least two independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001; n.s., not significant.

Article Snippet: The splenic CD4+ T cells were purified using immunomagnetic positive selection (EasySepTM mouse CD4+ positive selection Kit, 18952, Stemcell technologies, Canada).

Techniques: In Vitro, Cell Culture

Journal: Theranostics

Article Title: Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis

doi: 10.7150/thno.48080

Figure Lengend Snippet: Sirt1 is a mediator of hUC-MSCs increasing senescence of splenic CD4+ T cells in MRL/ lpr mice. (A) Western blotting showing the expression of Sirt1, p21, p16, p53 and acetylation of p53 in EX527 and DMSO treated MRL/ lpr splenic CD4+ T cells. (B) MRL/ lpr splenic CD4+ T cells were pretreated with SRT1720 12 h before exposed to hUC-MSCs for 24-48 h, western blotting showing the expression of p21, p16, p53 and acetylation of p53. GAPDH was used as a protein loading control. All experimental data were verified in at least three independent experiments. * p < 0.05; ** p < 0.01.

Article Snippet: The splenic CD4+ T cells were purified using immunomagnetic positive selection (EasySepTM mouse CD4+ positive selection Kit, 18952, Stemcell technologies, Canada).

Techniques: Western Blot, Expressing, Control

Journal: Theranostics

Article Title: Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis

doi: 10.7150/thno.48080

Figure Lengend Snippet: hUC-MSCs induced miR-199a-5p can increase MRL/ lpr splenic CD4+ T cell senescence. (A) qPCR analysis of the levels of ten potential miRNAs in WT mice, PBS-treated MRL/ lpr mice and hUC-MSCs-treated MRL/ lpr mice splenic CD4+ T cells. (B-D) qPCR and western blotting analysis of the levels of miR-199a-5p, Sirt1, p21, p16 and acetyl-p53 in vehicle and miR-199a-5p mimic-treated MRL/ lpr splenic CD4+ T cells. (E-F) qPCR and western blotting analysis of the levels of Sirt1, p21, p16 and acetyl-p53 in vehicle and miR-199a-5p inhibitor-treated WT splenic CD4+ T cells. (G-I) MRL/ lpr splenic CD4+ T cells and hUC-MSCs were cultured alone or together in the presence or absence of miR-199a inhibitor using a transwell system. MiR-199a-5p, Sirt1, p21, p16 and acetyl-p53 were quantified in hUC-MSCs (the first bar) or splenic CD4+ T cells (the last three bars). GAPDH was used as a protein loading control. All experimental data were verified in at least two independent experiments. * p < 0.05; ** p < 0.01.

Article Snippet: The splenic CD4+ T cells were purified using immunomagnetic positive selection (EasySepTM mouse CD4+ positive selection Kit, 18952, Stemcell technologies, Canada).

Techniques: Western Blot, Cell Culture, Control

Journal: Theranostics

Article Title: Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis

doi: 10.7150/thno.48080

Figure Lengend Snippet: MiR-199a-5p agomir treatment increases senescence of MRL/ lpr splenic CD4+ T cells. (A) Experimental outline. CD4+ T cells were harvested to measures miR-199a-5p (B), Sirt1 (C), p21 and p16 (D). GAPDH was used as a protein loading control. (n = 6 per group). * p < 0.05; ** p < 0.01.

Article Snippet: The splenic CD4+ T cells were purified using immunomagnetic positive selection (EasySepTM mouse CD4+ positive selection Kit, 18952, Stemcell technologies, Canada).

Techniques: Control